Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study
Fondazione Michelangelo · National Taiwan University Hospital · +14 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
382
total citations
- FWCI
- 32.35
- Percentile
- 100%
- References
- 20
Citations per year
Authors
20Topics & keywords
Topics
Keywords
- Medicine
- Atezolizumab
- Triple-negative breast cancer
- Oncology
- Internal medicine
- Carboplatin
- Regimen
- Breast cancer
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- BCBreast Cancer Research Foundation
- AAmgen
- BSBristol-Myers Squibb
- ELEli Lilly and Company
- PPfizer
- AAstraZeneca
- SSanofi
- GSGilead Sciences
- TPTeva Pharmaceutical Industries
- CCelgene
- FHF. Hoffmann-La Roche
- GHGenomic Health
- LLLes Laboratories Pierre Fabre
- MFMater Foundation
- SSeagen
- ICIrish Cancer Society
- EEisai
- ITIstituto Toscano Tumori
- UDUniversità degli Studi di Genova
- PMParacelsus Medizinische Privatuniversität
- UKUniversitätsklinikum Köln
- PPharmaMar
- IIpsen
- UHUniversitätsklinikum Heidelberg
- GGenentech
- CPChugai Pharmaceutical
- DSDaiichi Sankyo Europe